Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $78.0 million.

  • Harvard Bioscience's Liabilities and Shareholders Equity fell 4057.25% to $78.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $364.5 million, marking a year-over-year decrease of 3130.86%. This contributed to the annual value of $126.6 million for FY2024, which is 780.54% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Liabilities and Shareholders Equity is $78.0 million, which was down 4057.25% from $80.1 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Liabilities and Shareholders Equity high stood at $162.3 million for Q4 2021, and its period low was $78.0 million during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $142.9 million (2023), whereas its average is $134.2 million.
  • As far as peak fluctuations go, Harvard Bioscience's Liabilities and Shareholders Equity surged by 449.26% in 2022, and later crashed by 4057.25% in 2025.
  • Over the past 5 years, Harvard Bioscience's Liabilities and Shareholders Equity (Quarter) stood at $162.3 million in 2021, then fell by 10.46% to $145.4 million in 2022, then decreased by 5.5% to $137.4 million in 2023, then fell by 7.81% to $126.6 million in 2024, then tumbled by 38.42% to $78.0 million in 2025.
  • Its last three reported values are $78.0 million in Q3 2025, $80.1 million for Q2 2025, and $79.8 million during Q1 2025.